Adamas Pharma EPS beats by $0.10, misses on revenue
- BySeeking Alpha-
Adamas Pharma (NASDAQ:ADMS): Q1 GAAP EPS of -$0.36 beats by $0.10.Revenue of $19.31M (+33.4% Y/Y) misses by $0.35M.Press Release
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Adamas Pharma (ADMS)
NASDAQ
Symbol | Exchange | Currency |
|---|
4.830
+0.030(+0.62%)
- Volume:40,985
- Bid/Ask:4.810/4.850
- Day's Range:4.770 - 4.890
ADMS Overview
- Prev. Close
- 4.8
- Day's Range
- 4.77-4.89
- Revenue
- 79.29M
- Open
- 4.85
- 52 wk Range
- 2.43-9.15
- EPS
- -1.79
- Volume
- 40,985
- Market Cap
- 219.32M
- Dividend (Yield)
- N/A(N/A)
- Average Vol. (3m)
- 301,565
- P/E Ratio
- -
- Beta
- 2.69
- 1-Year Change
- 90.48%
- Shares Outstanding
- 45,408,095
- Next Earnings Date
- Aug 12, 2021
What is your sentiment on Adamas Pharma?
or
Vote to see community's results!
Adamas Pharma News
- Adamas Pharmaceuticals stock under pressure on $55M equity raise
- BySeeking Alpha-
Adamas Pharmaceuticals (ADMS) -7%premarket on pricing public offering of 12.5M common shares at $4.40/share, for gross proceeds of $55M.Underwriters' over-allotment is an...
- Adamas Pharmaceuticals launches follow-on public offering
- BySeeking Alpha-
Adamas Pharmaceuticals (ADMS) announces that it has commenced an underwritten public offering.The company intends to grant the underwriters a 30-day option to purchase up to an...
Adamas Pharma Analysis
- Cigna (CI) to Post Q1 Earnings: Will It Deliver a Beat?
Cigna Corporation (NYSE:CI) CI is set to report first-quarter 2021 results on May 7, before the opening bell.In the fourth quarter of 2020, the company’s earnings of $3.51...
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Sell | Strong Sell | Strong Sell |
| Technical Indicators | Buy | Buy | Strong Buy | Strong Sell | Sell |
| Summary | Neutral | Neutral | Neutral | Strong Sell | Strong Sell |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 371.88 | 377.54 | 367.00 | +4.07 | +1.11% | 13.99M | NASDAQ | |||
| 2,720.30 | 2,765.00 | 2,706.70 | +82.3 | +3.12% | 3.12M | NASDAQ | |||
| 167.36 | 177.12 | 164.38 | -11.18 | -6.26% | 3.20M | NYSE | |||
| 43.56 | 43.74 | 42.26 | +1.46 | +3.47% | 34.09M | NYSE | |||
| 53.18 | 53.92 | 52.94 | 0.00 | 0.00% | 16.47M | NASDAQ | |||
| 15.82 | 16.32 | 14.02 | +3.09 | +24.27% | 95.00M | NASDAQ | |||
| 194.62 | 196.40 | 189.76 | +8.55 | +4.59% | 24.87M | NYSE | |||
| 38.38 | 39.55 | 36.08 | +0.37 | +0.97% | 56.91M | NYSE | |||
| 194.20 | 196.46 | 189.95 | +2.12 | +1.10% | 13.24M | NASDAQ | |||
| 21.14 | 21.25 | 20.91 | +0.15 | +0.71% | 5.72M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 6.20 | 6.245 | 6.11 | +0.050 | +0.81% | 6.74M | NYSE | |||
| 6.12 | 6.66 | 5.90 | +0.61 | +11.07% | 117.55M | NYSE | |||
| 141.52 | 142.46 | 140.15 | +0.59 | +0.42% | 3.47M | NASDAQ | |||
| 41.21 | 41.87 | 39.80 | +1.85 | +4.70% | 46.70M | NYSE |
Adamas Pharma Company Profile
Adamas Pharma Company Profile
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer’s type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Read More
- 2020-06-05 16:32:15
Adamas ? is it worths to entry ? - 2018-09-19 16:27:50
Pressure to discuss the sale of the company seems to be growing up. https://chn.ge/2OEI2kD - 2016-11-17 16:36:21All 8 analyst covering ADMS recommend "buy." The average target price consensus for the next 12 months is $34 which is 110% ROI at its current price of $16.16.
- 2017-09-01 12:57:56
revenue is going to increase exponentially once this parkinsons drug gets out in circulation in January 18 .. that will be good for top and bottom line numbers come earning seasons.$$$$$. and mist of all definitely great for patients suffering. - 2020-08-13 11:40:00Huh, so price targets me nothing. The more you know (it's not getting anywhere near $30 in the next 3 months)
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.